Author: Qi, Yan; Hu, Xin; Chen, Jing; Ying, Xiaobin; Shi, Yan
Title: The Risk Factors of VTE and Survival Prognosis of Patients With Malignant Cancer: Implication for Nursing and Treatment Cord-id: mcofp8ga Document date: 2020_10_29
ID: mcofp8ga
Snippet: Venous thromboembolism (VTE) is very common in patients with malignant cancer. We aimed to conduct a retrospective analysis on the risk factors of VTE and its survival prognosis of patients with malignant cancer, to provide evidence into the management of VTE. Patients with malignant cancer treated in our hospital were selected. The characteristic of patients and related lab detection results including activated partial thromboplastin time (APTT), plasma prothrombin time (PT) and thrombin coagul
Document: Venous thromboembolism (VTE) is very common in patients with malignant cancer. We aimed to conduct a retrospective analysis on the risk factors of VTE and its survival prognosis of patients with malignant cancer, to provide evidence into the management of VTE. Patients with malignant cancer treated in our hospital were selected. The characteristic of patients and related lab detection results including activated partial thromboplastin time (APTT), plasma prothrombin time (PT) and thrombin coagulation time (TT), fibrinogen (FIB), thrombin AT-Ⅲ complex (TAT) and D-dimer (D-D) were collected and analyzed. And logistic regression analyses were performed to identify the potential risk factors. And ROC curves were established to evaluate their predictive ability of VTE for patients with malignant cancers. A total of 286 patients were included, of which 63 patients had VTE, the incidence of VTE in patients with malignant cancers was 22.03%. There were significant differences on the D-D, TAT level between VTE and no VTE patients (all P < 0.05). The survival condition of VTE patients was significantly worse than that of no VTE patients(P = 0.017). D-D (RR7.895, 3.228∼19.286) and TAT (6.122, 2.244∼16.695) were risk factors of VTE for patients with cancers (all P < 0.05). The area under the curve (AUC) of D-D, TAT and combined use was 0.764, 0.698, 0.794 respectively, and the cutoff value for D-D, TAT was 1.835mg/L and 4.58μg/L respectively. For cancer patients with D-D >1.835 mg/L and TAT >4.58 μg/L, early interventions are needed for the prophylaxis of VTE.
Search related documents:
Co phrase search for related documents- abnormal coagulation and logistic regression: 1, 2, 3, 4
- abnormal coagulation and logistic regression analysis: 1, 2
- abnormal coagulation and low molecular weight: 1, 2, 3, 4, 5, 6, 7
- abnormal coagulation and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute myocardial infarction and admission treatment: 1, 2, 3
- acute myocardial infarction and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute myocardial infarction and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8
- acute myocardial infarction and long term follow: 1, 2, 3
- acute myocardial infarction and low molecular weight: 1, 2, 3
- acute myocardial infarction and low molecular weight heparin: 1, 2, 3
- acute myocardial infarction and low quality: 1, 2, 3
- admission treatment and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission treatment and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- admission treatment and low molecular weight: 1, 2, 3, 4
- admission treatment and low molecular weight heparin: 1, 2, 3, 4
- admission treatment and low quality: 1, 2, 3, 4, 5
- logistic regression and low molecular weight: 1, 2, 3, 4, 5, 6, 7
- logistic regression and low molecular weight heparin: 1, 2, 3, 4, 5, 6
- logistic regression and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
Co phrase search for related documents, hyperlinks ordered by date